Latham & Watkins Advised Goldman Sachs in $158 million TORL BioTherapeutics Funding Round
Latham & Watkins Advised Goldman Sachs in $158 million TORL BioTherapeutics Funding Round Law firm Latham & Watkins advised Goldman Sachs Asset Management in TORL BioTherapeutics LLC's recent financing, which saw the biopharmaceutical company raise $158 million in a Series B funding round. The funding was led by Goldman Sachs Asset Management, with participation from Bristol...
ToRead the Full Story, Subscribe to
Access the exclusive LEGAL ERAStories,Editorial and Expert Opinion
Latham & Watkins Advised Goldman Sachs in $158 million TORL BioTherapeutics Funding Round
Law firm Latham & Watkins advised Goldman Sachs Asset Management in TORL BioTherapeutics LLC's recent financing, which saw the biopharmaceutical company raise $158 million in a Series B funding round.
The funding was led by Goldman Sachs Asset Management, with participation from Bristol Myers Squibb, Deep Track Capital, Moore Strategic Ventures, Perceptive Xontogeny Venture Fund, UC Office of the Chief Investment Officer, and Vertex Ventures HC. Existing investors including Alexandria Venture Investments and OCV Partners also participated in the financing.
The Latham & Watkins team was led by Saad Khanani, a partner based in the firm's Bay Area office. Chicago-based associates Omar Ammash and Jay Trewn also worked on the deal.
The firm provided additional advice on tax matters through Bay Area partner Grace Lee and associate Alex Farris, and on benefits and compensation matters through partner Julie Crisp, who is based in Century City and the Bay Area.
